First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened? Burtness B. J Clin Oncol 2023 Mar 6:JCO2202349. doi: 10.1200/JCO.22.02349.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Burtness B. First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened? J Clin Oncol 2023 Mar 6:JCO2202349. doi: 10.1200/JCO.22.02349.
PMID: 36877893